Search research articles
Contact Us
Filters
Showing results (301-310 of 447) with videos related to
Page
of 45
Sort By:
Breast Cancer Research and Treatment
|
February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Miguel Martin, Jan C Brase, Amparo Ruiz, et al.
Bioengineering & Translational Medicine
|
November 18, 2024
Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple-negative breast cancer
Natasha Vinod, Duhyeong Hwang, Sloane Christian Fussell, et al.
Nano Letters
|
December 15, 2016
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer
Charles J Bowerman, James D Byrne, Kevin S Chu, et al.
Cell Reports
|
July 14, 2015
Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation
Ze-Yi Zheng, Lin Tian, Wen Bu, et al.
Nature
|
April 10, 2015
A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis
Elvin Wagenblast, Mar Soto, Sara Gutiérrez-Ángel, et al.
Ebiomedicine
|
November 14, 2022
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
Valentina Guarneri, Fara Bras-Maristany, Maria Vittoria Dieci, et al.
The Journal of Clinical Investigation
|
August 16, 2021
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Andrew S Truong, Mi Zhou, Bhavani Krishnan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 6, 2014
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)
William M Sikov, Donald A Berry, Charles M Perou, et al.
Nature Communications
|
January 24, 2013
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
Jessica Bockhorn, Rachel Dalton, Chika Nwachukwu, et al.
Biorxiv : the Preprint Server for Biology
|
March 16, 2026
Transcriptomic profiling of mouse mammary tumors enables prognostic and predictive biomarker discovery for human breast cancers
Matthew D Sutcliffe, Kevin R Mott, Tulay Yilmaz-Swenson, et al.
Page
of 45
Search research articles
Search
Showing results (301-310 of 447) with videos related to
Sort By:
Page
of 45
Breast Cancer Research and Treatment
|
February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Miguel Martin, Jan C Brase, Amparo Ruiz, et al.
Bioengineering & Translational Medicine
|
November 18, 2024
Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple-negative breast cancer
Natasha Vinod, Duhyeong Hwang, Sloane Christian Fussell, et al.
Nano Letters
|
December 15, 2016
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer
Charles J Bowerman, James D Byrne, Kevin S Chu, et al.
Cell Reports
|
July 14, 2015
Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation
Ze-Yi Zheng, Lin Tian, Wen Bu, et al.
Nature
|
April 10, 2015
A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis
Elvin Wagenblast, Mar Soto, Sara Gutiérrez-Ángel, et al.
Ebiomedicine
|
November 14, 2022
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
Valentina Guarneri, Fara Bras-Maristany, Maria Vittoria Dieci, et al.
The Journal of Clinical Investigation
|
August 16, 2021
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Andrew S Truong, Mi Zhou, Bhavani Krishnan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 6, 2014
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)
William M Sikov, Donald A Berry, Charles M Perou, et al.
Nature Communications
|
January 24, 2013
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
Jessica Bockhorn, Rachel Dalton, Chika Nwachukwu, et al.
Biorxiv : the Preprint Server for Biology
|
March 16, 2026
Transcriptomic profiling of mouse mammary tumors enables prognostic and predictive biomarker discovery for human breast cancers
Matthew D Sutcliffe, Kevin R Mott, Tulay Yilmaz-Swenson, et al.
Page
of 45